• Special Populations for Toripalimab Use

  Toripalimab (a PD-1 inhibitor) should be used in special populations strictly following the principle of individualization. Key populations include ch···【Read More】

  Update: 2026-02-11Source: Haiou HealthViews: 77

• NMPA Grants Conditional Approval for Disitamab Vedotin for Injection

  On June 9, 2021, the National Medical Products Administration (NMPA) granted conditional approval for Disitamab Vedotin for Injection (brand name: Aid···【Read More】

  Update: 2026-02-10Source: Haiou HealthViews: 76

• Who is strictly prohibited from using Disitamab Vedotin?

  Individuals with hypersensitivity to this product:Such patients may develop severe allergic reactions or even aggravate pre-existing diseases after ad···【Read More】

  Update: 2026-02-10Source: Haiou HealthViews: 74

• What are the dosage forms and specifications of Disitamab Vedotin?

  Currently, the main dosage form of this drug is injection, with a fill volume of 60 mg per vial.【Read More】

  Update: 2026-02-10Source: Haiou HealthViews: 75

• What should be done in case of overdosage of Disitamab Vedotin?

  In the event of overdosage, immediately observe the patient for abnormal reactions such as dyspnea and tachycardia.Contact a doctor promptly and admin···【Read More】

  Update: 2026-02-10Source: Haiou HealthViews: 75

• What other precautions should be noted during treatment with Disitamab Vedotin?

  It is recommended that female patients of childbearing potential or spouses of male patients undergo a pregnancy test (optional) before initiation of ···【Read More】

  Update: 2026-02-10Source: Haiou HealthViews: 74

• Is it allowed to take other similar therapeutic agents concurrently during treatment with Disitamab

  This is not clear. Please consult a doctor or pharmacist and use the drug as prescribed.【Read More】

  Update: 2026-02-10Source: Haiou HealthViews: 81

• Can Disitamab Vedotin still be used if it has expired or its outer packaging is damaged?

  No. The drug may lose its efficacy and even cause adverse reactions.【Read More】

  Update: 2026-02-10Source: Haiou HealthViews: 74

• Price of Disitamab Vedotin for Injection

  Disitamab Vedotin for Injection (generic name: Disitamab Vedotin) is an antibody-drug conjugate (ADC) targeting HER2-expressing solid tumors (e.g., ga···【Read More】

  Update: 2026-02-10Source: Haiou HealthViews: 74

• Price of Disitamab Vedotin

  Disitamab vedotin is a targeted drug indicated for the treatment of specific HER2-expressing solid tumors (including gastric cancer, urothelial carcin···【Read More】

  Update: 2026-02-10Source: Haiou HealthViews: 78

• How Much Does Disitamab Vedotin Cost?

  The pricing of Disitamab Vedotin varies by dosage, region and hospital policies. A single vial generally costs approximately US$$2,170 to U$$2,893. Th···【Read More】

  Update: 2026-02-10Source: Haiou HealthViews: 73

• Disitamab Vedotin – Prescribing Information

  Disitamab vedotin is a HER2‑targeted antibody‑drug conjugate (ADC). It acts by specifically binding to the HER2 protein on the surface of tumor cells ···【Read More】

  Update: 2026-02-10Source: Haiou HealthViews: 72

• Hengrui’s Innovative Drug Fluzoparib Monotherapy or Fluzoparib Combined with Apatinib Approved for T

  On December 3, 2024, Hengrui Pharmaceutical Co., Ltd. received the Drug Registration Certificates forFuzuloparib Capsules and Apatinib Mesylate Tablet···【Read More】

  Update: 2026-02-09Source: Haiou HealthViews: 75

• Hengrui Medicine’s Innovative Drug Fuzuloparib in Combination with Bevacizumab Approved for Clinical

  On September 8, 2021, Jiangsu Hengrui Pharmaceutical Co., Ltd. and its subsidiary Suzhou Sundia Biotechnology Co., Ltd. received the Notice of Approva···【Read More】

  Update: 2026-02-09Source: Haiou HealthViews: 85

• NMPA Approves Fuzuloparib Capsules for Market Launch

  On December 14, 2020, the National Medical Products Administration (NMPA) granted conditional approval for the marketing of Fuzuloparib Capsules (bran···【Read More】

  Update: 2026-02-09Source: Haiou HealthViews: 83